title: Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C.
abstract: The pathogenic mechanisms of accelerated graft fibrosis in hepatitis C recurrence after liver transplantation (LT) are not well established. The aim of the study was to assess whether a greater activation of hepatic stellate cells (HSC), the major collagen-producing cells in the liver, can occur in these patients as compared to non-LT patients with chronic hepatitis C. We determined the amount of activated HSC by computer-based morphometric analysis of alpha-smooth muscle actin (alphaSMA)-positive cells and the hepatic TGFbeta(1) expression by immunohistochemistry in 46 LT patients with hepatitis C recurrence, 35 non-LT patients with chronic hepatitis C, and 16 controls. Hepatic alphaSMA and TGFbeta(1) expression was higher in LT patients with hepatitis C recurrence than in controls and was correlated with fibrosis stage and progression rate. No significant difference in alphaSMA and TGFbeta(1) expression was observed between LT and non-LT patients with hepatitis C, with the exception of a higher transforming growth factor beta-1 (TGFbeta(1)) expression in non-LT patients in the early stages of fibrosis. LT patients receiving cyclosporine (CsA) or tacrolimus (FK) had a similar fibrosis progression rate and alphaSMA and TGFbeta(1) expression. In conclusion, the accelerated fibrosis observed in LT patients with hepatitis C recurrence does not seem to be related to a greater amount of activated HSC and TGFbeta(1) expression in the grafts of these patients as compared to non-LT patients with chronic hepatitis C. In LT patients, the amount of activated HSC and TGFbeta(1) expression correlated with fibrosis stage and progression, without any apparent influence of the type of calcineurin inhibitor administered.
authors.affiliation: Liver Unit, Centro de Investigación Biomédica en Red de Enfermedades hepaticos y digestivas, Barcelona, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Cisneros
authors.forename: Maria-Carlota
authors.initials: MC
authors.lastname: Londoño
authors.forename: Carmen
authors.initials: C
authors.lastname: Blasco
authors.forename: Ramón
authors.initials: R
authors.lastname: Bataller
authors.forename: Rosa
authors.initials: R
authors.lastname: Miquel
authors.forename: Miquel
authors.initials: M
authors.lastname: Bruguera
authors.forename: Pere
authors.initials: P
authors.lastname: Ginès
authors.forename: Antoni
authors.initials: A
authors.lastname: Rimola
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000473:pathology*; D019698:Hepatitis C, Chronic / Q000473:pathology*; D022781:Hepatocytes / Q000473:pathology / Q000821:virology*; D006801:Humans; D007150:Immunohistochemistry; D008103:Liver Cirrhosis / Q000473:pathology / Q000821:virology; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence